This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News for APRE
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
Other News for APRE
Buy Rating on Aprea Therapeutics: Outshining Competitors with Selective and Potent WEE1 Inhibitor APR-1051
Buy Rating Affirmed for Aprea Therapeutics on APR-1051’s Promising Safety and Efficacy Profile
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
Aprea Therapeutics’ APR-1051: Poised for Leadership in WEE1 Inhibition with Promising Clinical and Market Potential
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Gossamer Bio (GOSS) and Aprea Therapeutics (APRE)